We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gritstone (GRTS) to Begin Coronavirus Vaccine Study, Stock Up
Read MoreHide Full Article
Gritstone Oncology, Inc. (GRTS - Free Report) announced that it is advancing development of a second generation COVID-19 vaccine candidate, which has the potential to provide both prolonged protection and potency against spike mutants of SARS-CoV-2, the virus that causes COVID-19.
Shares of Gritstone soared 248.5% on Tuesday, following the announcement of the news. In fact, the stock has surged 106.4% in the past year compared with the industry’s increase of 11.7%.
The company is looking to begin a phase I study on the vaccine candidate, which is being supported by National Institute of Allergy and Infectious Diseases through the Infectious Diseases Clinical Research Consortium. The Bill & Melinda Gates Foundation has supported the preclinical evaluation of the vaccine.
Per the press release, Gritstone uses both self-amplifying mRNA and adenoviral vectors to deliver the SARS-CoV-2 viral antigens. The company has access to validated SARS-CoV-2 epitopes that have been identified through studies on patients who are recovering from the disease. Using these epitopes along with its proprietary Gritstone EDGE and vaccine platform technologies, Gritstone is looking to develop a novel vaccine against COVID-19, containing spike (similar to first generation vaccines) but also additional viral epitopes that offer targets for T cell immunity to COVID-19.
The next-generation vaccine may have pan-SARS/coronavirus potential to protect against future coronavirus pandemics. If successfully developed, the vaccine may provide more comprehensive viral protection compared to the currently available vaccines.
We note that several companies have already come up with vaccines for fighting the COVID-19 virus.
Pfizer (PFE - Free Report) and its partner BioNTech’s mRNA-based COVID-19 vaccine, BNT162b2, is approved for emergency/temporary/conditional use in more than 40 countries, including the United States and 27 EU member countries. Another mRNA-based COVID-19 vaccine candidate, mRNA-1273, developed by Moderna, Inc. (MRNA - Free Report) has been approved for emergency/temporary use in the United States and Europe.
Meanwhile, AstraZeneca’s (AZN - Free Report) adenovirus-based coronavirus vaccine candidate, AZD1222, is approved for emergency use in the United Kingdom and India.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Gritstone (GRTS) to Begin Coronavirus Vaccine Study, Stock Up
Gritstone Oncology, Inc. (GRTS - Free Report) announced that it is advancing development of a second generation COVID-19 vaccine candidate, which has the potential to provide both prolonged protection and potency against spike mutants of SARS-CoV-2, the virus that causes COVID-19.
Shares of Gritstone soared 248.5% on Tuesday, following the announcement of the news. In fact, the stock has surged 106.4% in the past year compared with the industry’s increase of 11.7%.
The company is looking to begin a phase I study on the vaccine candidate, which is being supported by National Institute of Allergy and Infectious Diseases through the Infectious Diseases Clinical Research Consortium. The Bill & Melinda Gates Foundation has supported the preclinical evaluation of the vaccine.
Per the press release, Gritstone uses both self-amplifying mRNA and adenoviral vectors to deliver the SARS-CoV-2 viral antigens. The company has access to validated SARS-CoV-2 epitopes that have been identified through studies on patients who are recovering from the disease. Using these epitopes along with its proprietary Gritstone EDGE and vaccine platform technologies, Gritstone is looking to develop a novel vaccine against COVID-19, containing spike (similar to first generation vaccines) but also additional viral epitopes that offer targets for T cell immunity to COVID-19.
The next-generation vaccine may have pan-SARS/coronavirus potential to protect against future coronavirus pandemics. If successfully developed, the vaccine may provide more comprehensive viral protection compared to the currently available vaccines.
We note that several companies have already come up with vaccines for fighting the COVID-19 virus.
Pfizer (PFE - Free Report) and its partner BioNTech’s mRNA-based COVID-19 vaccine, BNT162b2, is approved for emergency/temporary/conditional use in more than 40 countries, including the United States and 27 EU member countries. Another mRNA-based COVID-19 vaccine candidate, mRNA-1273, developed by Moderna, Inc. (MRNA - Free Report) has been approved for emergency/temporary use in the United States and Europe.
Meanwhile, AstraZeneca’s (AZN - Free Report) adenovirus-based coronavirus vaccine candidate, AZD1222, is approved for emergency use in the United Kingdom and India.
Zacks Rank
Gritstone currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>